- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | 244 | GlobeNewswire (Europe) | ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion.Inflammasome ASC Inhibitor IC 100 is the next evolution... ► Artikel lesen | |
| Mi | ZyVersa Therapeutics, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 31.03. | ZyVersa Therapeutics GAAP EPS of -$4.18 | 1 | Seeking Alpha | ||
| ZYVERSA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 31.03. | ZyVersa Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 05.03. | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.12.25 | ZyVersa Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.11.25 | ZyVersa Therapeutics GAAP EPS of -$2.56, | 1 | Seeking Alpha | ||
| 19.11.25 | ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results | 184 | GlobeNewswire (Europe) | ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies - Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases... ► Artikel lesen | |
| 19.11.25 | ZyVersa Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.11.25 | ZyVersa Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 03.09.25 | ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression | 250 | GlobeNewswire (Europe) | ZyVersa is developing Cholesterol Efflux Mediator VAR 200 to mediate removal of damaging excess cholesterol and other lipids from the kidneys' filtration system. VAR 200 directly removes lipids from... ► Artikel lesen | |
| 13.08.25 | ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones | 519 | GlobeNewswire (Europe) | KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening... ► Artikel lesen | |
| 21.07.25 | ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress | 254 | GlobeNewswire (Europe) | WESTON, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment... ► Artikel lesen | |
| 08.07.25 | ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator VAR 200 in a Patient with ApoCII Amyloidosis | 628 | GlobeNewswire (Europe) | ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into... ► Artikel lesen | |
| 26.06.25 | ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD) | 263 | GlobeNewswire (Europe) | Initiation of patient recruitment marks a key milestone in the development of VAR 200, a potential first-in-class treatment for kidney disease addressing renal lipotoxicity.There are no available... ► Artikel lesen | |
| 20.05.25 | ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson's and Alzheimer's Diseases | 232 | GlobeNewswire (Europe) | Study results corroborate our recently published data demonstrating the critical role of microglial-driven inflammation in promoting accumulation and spread of toxic phosphorylated alpha-synuclein... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,465 | -0,44 % | Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht | DJ Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht
DOW JONES--Die Aktionäre von Qiagen können sich über eine höhere Dividende freuen. Wie es in der Einladung zur Hauptversammlung... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,560 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| HCW BIOLOGICS | 1,210 | -0,82 % | HCW Biologics Inc.: HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results | MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 81,09 | -0,06 % | Jefferies raises Apogee Therapeutics stock price target on trial outlook | ||
| PRAXIS PRECISION MEDICINES | 341,89 | -0,20 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| CG ONCOLOGY | 66,93 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| EVOTEC | 4,618 | -1,74 % | Evotec zapft den Kapitalmarkt an | Evotec platziert Wandelanleihen über 116,1 Mio. EUR und finanziert damit das Transformationsprogramm "Project Horizon". Die Evotec SE hat sich frisches Kapital über den Wandelanleihemarkt gesichert.... ► Artikel lesen | |
| BIONTECH | 76,40 | -2,98 % | Community Rückblick: wO-User zu BioNTech Quartalsbericht: "Oh wow, die Zahlen sind eine Katastrophe!" | © Foto: picture alliance / Laci Perenyi | Laci PerenyiBioNTech steht nach neuen Quartalszahlen und angekündigten Standortschließungen weiter unter Druck. Hohe Verluste, Umbau des Geschäfts und das Aus... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,710 | +0,09 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress | ||
| NUVALENT | 102,40 | +0,10 % | Nuvalent, Inc.: Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results | NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC
NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review... ► Artikel lesen | |
| JADE BIOSCIENCES | 23,355 | 0,00 % | Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update | Interim biomarker-rich Phase 1 data for JADE101 to be featured in an oral session at the 63rd European Renal Association Congress Phase 2 trial of JADE101 in IgA nephropathy patients expected to begin... ► Artikel lesen | |
| RELAY THERAPEUTICS | 12,205 | +0,04 % | H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) | ||
| TYRA BIOSCIENCES | 37,070 | +0,08 % | Tyra Biosciences GAAP EPS of -$0.64 | ||
| KYMERA THERAPEUTICS | 82,25 | +0,05 % | Kymera presents KT-621 atopic dermatitis trial data at conferences | ||
| BEAM THERAPEUTICS | 27,945 | +0,05 % | H.C. Wainwright reiterates Beam Therapeutics stock rating at buy |
ZYVERSA THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,42 % bei einem Aktienkurs von 0,310 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZYVERSA THERAPEUTICS INC finden Sie auf Wallstreet Online.